Skip to main content

Advertisement

SpringerLink
Log in

Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Osteoporosis represents an important cause of morbidity in adult rheumatoid arthritis (RA) patients who exhibit increased fracture risk. It is thought that osteoclast and its dysfunction which mediated by many cytokines are the principal pathogenesis of this bone disease, although the mechanisms are still not fully understood. Osteoprotegerin (OPG) and receptor activator of nuclear factor-kappa B ligand (RANKL) have been revealed in the pathogenesis of primary osteoporosis and other metabolic bone diseases. Thus, the aim of this study was to investigate the possible role of the OPG/RANKL system in RA-related bone loss. A total of 64 Chinese patients with RA and 60 healthy control subjects were involved. Serum levels of OPG and RANKL were measured by ELISA. BMD of nondominant forearm, lumbar spine(L1–4) and proximal femur, including femoral neck, Wards triangle, greater trochanter were assessed using dual-energy X-ray absorptiometry. RA patients had a higher incidence of osteoporosis (23/64, 35.9%) than that in healthy controls (9/60, 15.0%) (P < 0.0001). They displayed lower BMD values than controls at positions of all detected region. Compared with healthy controls, RA group showed significantly higher serum levels of RANKL (48.4 ± 12.5 vs. 23.0 ± 11.2 pmol/l, P < 0.0001), lower serum levels of OPG (106.2 ± 40.6 vs. 231.6 ± 65.6 pg/ml, P < 0.0001), and OPG/RANKL ratio (2.4 ± 0.7 vs. 7.0 ± 1.1, P < 0.0001). Multiple linear regression analysis revealed that in RA group, plasma rheumatoid factor concentration (β = −0.187, P = 0.031), swollen joint count (β = 0.567, P = 0.029), BMD at forearm (β = 0.324, P = 0.002), femoral Wards triangle (β = 0.370, P < 0.0001), and lumbar spine (β = 0.313, P = 0.003) were the contributors for serum OPG (R 2 = 0.718, P < 0.0001). Age (β = 0.241, P = 0.042) and BMD at femoral Wards triangle (β = −0.441, P < 0.0001) and lumbar spine (β = −0.320, P = 0.013) were the determinants for serum RANKL (R 2 = 0.616, P < 0.0001), while swollen joint count (β = 1.029, P = 0.019) and BMD at femoral neck (β = 0.285, P = 0.042) for serum OPG/RANKL ratio (R 2 = 0.279, P < 0.011). Analysis of logistic regression showed age (P = 0.004, OR = 1.156, 95% CI: 1.047–1.276) and the level of C-reactive protein (P = 0.028, OR = 1.019, CI 95%: 1.002–1.036) in peripheral blood of RA were the risk factors for the occurrence of osteoporosis in RA, while OPG/RANKL ratio (P = 0.007, OR = 0.035, CI 95%: 0.003–0.400) was the unique protective factor. These data suggest that, in Chinese RA patients, an altered modulation of the OPG/RANKL system resulting in increased RANKL and decreased OPG in peripheral blood, could contribute to the bone loss characteristic and the generation of osteoporosis in these patients. Changes of ratio of OPG/RANKL might be a protective mechanism against the accelerated bone loss in RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Romas E, Gillespie MT, Martin TJ (2002) Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis. Bone 30:340–346 (PubMed: 11856640)

    Article  PubMed  CAS  Google Scholar 

  2. Abu-Amer Y, Abbas S, Hirayama T (2004) TNF receptor type I regulates RANK ligand expression by stromal cells and modulates osteoclastogenesis. J Cell Biochem 93:980–989 (PubMed: 15389885)

    Article  PubMed  CAS  Google Scholar 

  3. Gravallese EM, Goldring SR (2000) Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 43:2143–2151 (PubMed: 11037873)

    Article  PubMed  CAS  Google Scholar 

  4. Hofbauer LC, Heufelder AE (2001) The role of osteoprotegerin and receptor activator of nuclear factor κB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 44:253–259 (PubMed: 11229454)

    Article  PubMed  CAS  Google Scholar 

  5. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E et al (2000) Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 43:250–258 (PubMed: 10693863)

    Article  PubMed  CAS  Google Scholar 

  6. Saidenberg KN, Con’ado A, Lemeiter D (2004) TNF-α antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35:1200–1207 (PubMed:15542046)

    Article  Google Scholar 

  7. Khosla S (2001) Minireview: the OPG/RANKL/RANK system. Endocrinology 142:5050–5055 (PubMed:11713196)

    Article  PubMed  CAS  Google Scholar 

  8. Page G, Miossec P (2005) RANK and RANKL expression as markers of dendritic cell -T cel1 interactions in paired samples of rheumatoid synovium and lymph nodes. Arthritis Rheum 52:2307–2312 (PubMed:16052586)

    Article  PubMed  CAS  Google Scholar 

  9. Kostenuik PJ, Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharm Des 7:613–635 (PubMed:11375772)

    Article  PubMed  CAS  Google Scholar 

  10. Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T et al (1998) Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610–615 (PubMed: 9647741)

    Article  PubMed  CAS  Google Scholar 

  11. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315–323 (PubMed: 9950424)

    Article  PubMed  CAS  Google Scholar 

  12. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324 (PubMed: 3358796)

    Article  PubMed  CAS  Google Scholar 

  13. Liu Z, Piao J, Pang L, Qing X, Nan S, Pan Z et al (2002) The diagnostic criteria for primary osteoporosis and the incidence of osteoporosis in China. J Bone Miner Metab 20:181–189 (PubMed: 12115062)

    Article  PubMed  Google Scholar 

  14. Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331–337 (PubMed: 11685647)

    Article  PubMed  CAS  Google Scholar 

  15. Gravallese EM (2002) Bone destruction in arthritis. Ann Rheum Dis 61(Suppl 2):ii84–ii86 (PubMed: 12379632)

    PubMed  Google Scholar 

  16. Sinigaglia L, Varenna M, Girasole G, Bianchi G (2006) Epidemiology of osteoporosis in rheumatic diseases. Rheum Dis Clin North Am 32:631–658 (PubMed: 17288969)

    Article  PubMed  Google Scholar 

  17. Bekker PJ, Holloway D, Nakanishi A, Arrighi HM, Leese PT, Dunstan CR (2001) Osteoprotegerin (OPG) has potent and sustained antiresorptive activity in post menopausal women. J Bone Miner Res 16:348–360 (PubMed:11204435)

    Article  PubMed  CAS  Google Scholar 

  18. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy R et al (1997) Osteoprotegerina: a noval secreted protein involved in the regulation of bone density. Cell 89:309–319 (PubMed: 9108485)

    Article  PubMed  CAS  Google Scholar 

  19. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176 (PubMed:9568710)

    Article  PubMed  CAS  Google Scholar 

  20. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM et al (1997) TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 86:2075–2080 (PubMed:9396779)

    Article  Google Scholar 

  21. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304–309 (PubMed: 10580503)

    Article  PubMed  CAS  Google Scholar 

  22. Ziolkowska M, Kurowska M, Radzikowska A, Luszczykiewicz G, Wiland P, Dziewczopolski W et al (2002) High levels of Osteoprotegerin and soluble receptor activator of nuclear factor κ B ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatment. Arthritis Rheum 46:1744–1753 (PubMed: 12124857)

    Article  PubMed  CAS  Google Scholar 

  23. Skoumal M, Kolarz G, Haberhauer G, Woloszczuk W, Hawa G, Klingler A (2005) Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int 26:63–69 (PubMed: 15889303)

    Article  PubMed  CAS  Google Scholar 

  24. Kotake S, Udagawa N, Hakoda M, Mogi M, Yano K, Tsuda E et al (2001) Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum 44:1003–1012 (PubMed: 11352231)

    Article  PubMed  CAS  Google Scholar 

  25. Vanderborght A, Linsen L, Thewissen M, Geusens P, Raus J, Stinissen P (2004) Osteopmtegerin and receptor activator of nuclear factor-kappa B ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 31:1483–1490 (PubMed: 15290725)

    PubMed  CAS  Google Scholar 

  26. Haynes DR, Crotti TN, Capone M, Bain GI, Atkins GJ, Findlay DM (2001) Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 40:623–630 (PubMed: 11426018)

    Article  CAS  Google Scholar 

  27. Nosaka K, Miyamoto T, Sakai T, Mitsuya H, Suda T, Matsuoka M (2002) Mechanism of hypercalcemia in adult T-cell leukemia: overexpression of receptor activator of nuclear factor κB ligand on adult T-cell leukemia cells. Blood 99:634–640 (PubMed: 11781248)

    Article  PubMed  CAS  Google Scholar 

  28. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK (2000) Bone mineral density and frequency of osteoporosis in female patient with rheumatoid arthritis: result from 394 patients in the Olso county rheumatoid arthritis register. Arthritis Rheum 43:522–530 (PubMed: 10728744)

    Article  PubMed  CAS  Google Scholar 

  29. Urbanek R, Tlustochowicz W, Patola J, Głodzik J (2000) Incidence of osteoporosis in patients with rheumatoid arthritis. Przegl Lek 57:103–107 (PubMed: 10907352)

    PubMed  CAS  Google Scholar 

  30. Oelzner P, Franke S, Lehmann G, Eidner T, Müller A, Wolf G et al (2007) Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis relationship with bone mineral density, disease activity and bone turnover. Clin Rheumatol 26:2127–2135 (PubMed: 17541498)

    Article  PubMed  CAS  Google Scholar 

  31. Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE et al (2004) Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. Ann Rheum Dis 63:1576–1580 (PubMed: 15547081)

    Article  PubMed  CAS  Google Scholar 

  32. Saidenberg-Kermanac’h N, Cohen-Solal M, Bessis N, De Vernejoul MC, Boissier MC (2004) Role for osteoprotegerin in rheumatoid inflammation. Joint Bone Spine 71:9–13 (PubMed: 14769514)

    Article  PubMed  Google Scholar 

  33. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, The Denosumab Rheumatoid arthritis Study Group et al (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58:1299–1309 (PubMed: 18438830)

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We would like to thank all patients and professionals who participated in the study, particularly Mingming Zhang for his kindly help during the lab proc of measuring the levels of OPG, RANKL and BDM.

Author information

Authors and Affiliations

  1. Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, No 218 Jixi Street, Hefei, 230022, China

    Shengqian Xu, Yu Wang & Jianhua Xu

  2. Department of Internal Medicine, Ankang Hospital of Hefei Public Security Bureau, Hefei, China

    Jingqiu Lu

Authors
  1. Shengqian Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jingqiu Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jianhua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jianhua Xu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Xu, S., Wang, Y., Lu, J. et al. Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis. Rheumatol Int 32, 3397–3403 (2012). https://doi.org/10.1007/s00296-011-2175-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-2175-5

Keywords

Search

Navigation